EN
繁
简
About SSY Group
Company Profile
Chairman’s Statement
Directors and Senior Management
Corporate Video
Our Business
Major Products
Investor Relations
Announcements and Notices
Corporate Governance
Financial Reports
Presentations
Returns on Share Capital
Circulars
Shareholder Services
Corporate Information
News
Press Releases
Contact Us
IR and Media Contact
Announcements and Notices
Home
Investor Relations
Announcements and Notices
2020
Select Year
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Dec
30
VOLUNTARY ANNOUNCEMENT - AMBROXOL HYDROCHLORIDE INJECTION PASSED CONSISTENCY EVALUATION
Dec
02
VOLUNTARY ANNOUNCEMENT - MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION PASSED CONSISTENCY EVALUATION
Nov
10
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Nov
05
VOLUNTARY ANNOUNCEMENT - UPDATE ON BUSINESS DEVELOPMENT
Oct
30
UNAUDITED OPERATING RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2020
Oct
14
CHANGE OF NAME OF PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS
Aug
25
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020
Aug
21
VOLUNTARY ANNOUNCEMENT - SELECTION RESULTS OF NATIONAL CENTRALIZED MEDICINES PROCUREMENT
Aug
19
VOLUNTARY ANNOUNCEMENT - UPDATE ON BUSINESS DEVELOPMENT AND PRODUCT DEVELOPMENT
Aug
13
DATE OF BOARD MEETING
Aug
07
PROFIT WARNING
Jul
29
VOLUNTARY ANNOUNCEMENT - INTRA-GROUP RESTRUCTURING FOR POSSIBLE SPIN-OFF AND SEPARATE LISTING
Jul
22
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Jul
20
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
May
22
POLL RESULTS OF ANNUAL GENERAL MEETING 2020
Apr
24
CONTINUING CONNECTED TRANSACTION - REVISION OF ANNUAL CAP
Apr
20
Notice of Annual General Meeting
Apr
20
UNAUDITED OPERATING RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2020
Mar
30
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019
Mar
23
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Mar
18
DATE OF BOARD MEETING
Feb
24
VOLUNTARY ANNOUNCEMENT - UPDATE ON BUSINESS DEVELOPMENT
Feb
20
VOLUNTARY ANNOUNCEMENT - UPDATE ON BUSINESS DEVELOPMENT
Feb
19
INSIDE INFORMATION - Inclusion of Abidol in Diagnosis and Treatment Program for Novel Coronavirus Infected Pneumonia (Trial Version 6)
Feb
06
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Feb
05
INSIDE INFORMATION, UNUSUAL TRADING VOLUME AND PRICE MOVEMENTS, RESUMPTION OF TRADING
Feb
05
Trading Halt
Jan
29
VOLUNTARY ANNOUNCEMENT - UPDATE ON BUSINESS DEVELOPMENT
Jan
15
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT